Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aldeyra Therapeutics Inc ALDX

Healthcare Biotechnology
Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are... see more

Recent & Breaking News (NDAQ:ALDX)

Aldeyra Therapeutics Reports Full-Year 2020 Financial Results and Recent Business Highlights

Business Wire March 11, 2021

Aldeyra Therapeutics to Present at the OIS Dry Eye Innovation Showcase on March 11, 2021

Business Wire March 10, 2021

Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Full-Year 2020 Financial Results and Discuss Recent Business Highlights

Business Wire March 4, 2021

Aldeyra Therapeutics to Participate in Upcoming Virtual Investor Conferences

Business Wire March 2, 2021

Aldeyra Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference

Business Wire February 18, 2021

Aldeyra Therapeutics Announces Phase 3 TRANQUILITY Dry Eye Disease Trial Design

Business Wire February 4, 2021

Aldeyra Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Business Wire January 20, 2021

Aldeyra Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock

Business Wire January 13, 2021

Aldeyra Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

Business Wire January 13, 2021

Aldeyra Therapeutics to Participate in Fireside Chat at the H.C. Wainwright BioConnect 2021 Virtual Conference

Business Wire January 8, 2021

Aldeyra Therapeutics Announces Positive Top-Line Symptom and Sign Results from Run-In Cohort of Phase 3 TRANQUILITY Trial in Dry Eye Disease

Business Wire January 7, 2021

Aldeyra Therapeutics to Host Conference Call and Webcast to Discuss Top-Line Symptom, Redness, and Schirmer's Test Results from Run-in Cohort of Phase 3 TRANQUILITY Trial

Business Wire January 6, 2021

Aldeyra Therapeutics Announces Confirmation of Antiviral Activity of ADX-1612

Business Wire December 22, 2020

Aldeyra Therapeutics Announces Initiation of Phase 2 Clinical Trials of ADX-629, a First-in-Class Orally Administered RASP Inhibitor, for the Treatment of COVID-19, Atopic Asthma, and Psoriasis

Business Wire December 17, 2020

Aldeyra Announces First Patient Enrolled in the Phase 3 TRANQUILITY Trial of Reproxalap for the Treatment of Dry Eye Disease

Business Wire December 8, 2020

Aldeyra Therapeutics to Participate in the Jefferies and A.G.P./Alliance Global Partners Virtual Investor Conferences

Business Wire November 13, 2020

Aldeyra Therapeutics Announces Third-Quarter 2020 Financial Results and Provides Corporate Update

Business Wire November 5, 2020

Aldeyra to Participate in the American Academy of Ophthalmology Eyecelerator 2020 Virtual Conference on Friday, November 6

Business Wire November 4, 2020

Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Third-Quarter 2020 Financial Results and Corporate Update

Business Wire October 29, 2020

Aldeyra to Present New Reproxalap Data from Phase 2 Clinical Trial in Allergic Conjunctivitis at American Academy of Ophthalmology 2020 Annual Meeting

Business Wire October 22, 2020